Eli Lilly and Company $LLY Shares Sold by Westbourne Investments Inc.

Key Points

• Westbourne Investments Inc. reduced its stake in Eli Lilly and Company by 24.1%, now holding 2,155 shares worth approximately $1.68 million.
• Eli Lilly reported a quarterly EPS of $6.31, exceeding estimates, and announced a quarterly dividend of $1.50 per share, with a yield of 0.8%.
• Analyst ratings reflect mixed views, with one firm upgrading the stock to strong-buy, while another downgraded it from strong-buy to hold, resulting in an average rating of moderate buy.

Westbourne Investments Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 24.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,155 shares of the company's stock after selling 685 shares during the quarter. Westbourne Investments Inc.'s holdings in Eli Lilly and Company were worth $1,680,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Duquesne Family Office LLC increased its stake in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after acquiring an additional 32,640 shares during the last quarter. Corient IA LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at $570,000. LS Investment Advisors LLC grew its stake in shares of Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares in the last quarter. Cutter Capital Management LP acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at $14,866,000. Finally, Prism Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at $207,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 in the last quarter. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $9.41 during trading on Friday, hitting $753.52. 7,319,147 shares of the stock were exchanged, compared to its average volume of 3,181,974. The company has a fifty day moving average price of $738.37 and a two-hundred day moving average price of $771.89. The company has a market cap of $713.18 billion, a PE ratio of 49.25, a P/E/G ratio of 1.06 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $939.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a $1.50 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on LLY shares. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday. JPMorgan Chase & Co. decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a report on Tuesday. Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Cantor Fitzgerald decreased their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. Finally, Guggenheim decreased their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.